Reversal of direct oral anticoagulants
Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-07-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/reversal-of-direct-oral-anticoagulants-peer-reviewed-article-VHRM |
| _version_ | 1828475929928663040 |
|---|---|
| author | Almegren M |
| author_facet | Almegren M |
| author_sort | Almegren M |
| collection | DOAJ |
| description | Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and became widely used as an alternative for vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation, the need for effective reversal agents has increased, particularly for life-threatening bleeding episodes related to DOACs or to reverse medication effects during urgent interventions. In the absence of specific reversal agents, prothrombin complex concentrate (PCC) and activated PCC are reasonable options to reverse bleeding associated with DOACs. However, high-quality clinical evidence is lacking. Idarucizumab is the only agent approved by the US Food and Drug Administration to reverse the effects of dabigatran; andexanet alfa and ciraparantag are also under evaluation as reversal agents for DOACs. This review summarizes the current evidence for nonspecific and specific reversal of DOACs. Keywords: idarucizumab, andexanet alfa, ciraparantag, direct oral anticoagulant, reversal agents |
| first_indexed | 2024-12-11T06:21:08Z |
| format | Article |
| id | doaj.art-6c320c9924c1495aba065cc73a7c2119 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-11T06:21:08Z |
| publishDate | 2017-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-6c320c9924c1495aba065cc73a7c21192022-12-22T01:17:48ZengDove Medical PressVascular Health and Risk Management1178-20482017-07-01Volume 1328729233848Reversal of direct oral anticoagulantsAlmegren MMosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and became widely used as an alternative for vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation, the need for effective reversal agents has increased, particularly for life-threatening bleeding episodes related to DOACs or to reverse medication effects during urgent interventions. In the absence of specific reversal agents, prothrombin complex concentrate (PCC) and activated PCC are reasonable options to reverse bleeding associated with DOACs. However, high-quality clinical evidence is lacking. Idarucizumab is the only agent approved by the US Food and Drug Administration to reverse the effects of dabigatran; andexanet alfa and ciraparantag are also under evaluation as reversal agents for DOACs. This review summarizes the current evidence for nonspecific and specific reversal of DOACs. Keywords: idarucizumab, andexanet alfa, ciraparantag, direct oral anticoagulant, reversal agentshttps://www.dovepress.com/reversal-of-direct-oral-anticoagulants-peer-reviewed-article-VHRMIdarucizumabAndexanet alfaCiraparantagdirect oral anticoagulantreversal agents |
| spellingShingle | Almegren M Reversal of direct oral anticoagulants Vascular Health and Risk Management Idarucizumab Andexanet alfa Ciraparantag direct oral anticoagulant reversal agents |
| title | Reversal of direct oral anticoagulants |
| title_full | Reversal of direct oral anticoagulants |
| title_fullStr | Reversal of direct oral anticoagulants |
| title_full_unstemmed | Reversal of direct oral anticoagulants |
| title_short | Reversal of direct oral anticoagulants |
| title_sort | reversal of direct oral anticoagulants |
| topic | Idarucizumab Andexanet alfa Ciraparantag direct oral anticoagulant reversal agents |
| url | https://www.dovepress.com/reversal-of-direct-oral-anticoagulants-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT almegrenm reversalofdirectoralanticoagulants |